BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31810939)

  • 1. Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
    Inada M; Sato A; Shindo M; Yamamoto Y; Akasaki Y; Ichimura K; Tanuma SI
    Anticancer Res; 2019 Dec; 39(12):6743-6750. PubMed ID: 31810939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells.
    Inada M; Shindo M; Kobayashi K; Sato A; Yamamoto Y; Akasaki Y; Ichimura K; Tanuma SI
    PLoS One; 2019; 14(5):e0216358. PubMed ID: 31100066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
    Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
    Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo.
    Liu T; Li A; Xu Y; Xin Y
    Cancer Med; 2019 Feb; 8(2):751-760. PubMed ID: 30656846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
    Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
    J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.
    Tamada K; Nakajima S; Ogawa N; Inada M; Shibasaki H; Sato A; Takasawa R; Yoshimori A; Suzuki Y; Watanabe N; Oyama T; Abe H; Inoue S; Abe T; Yokomizo T; Tanuma S
    Biochem Biophys Res Commun; 2019 Apr; 511(3):665-670. PubMed ID: 30826057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
    Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
    J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
    Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
    J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

  • 13. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
    Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
    J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
    López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
    Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
    Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
    Chakrabarti M; Ray SK
    Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
    Rubner Y; Muth C; Strnad A; Derer A; Sieber R; Buslei R; Frey B; Fietkau R; Gaipl US
    Radiat Oncol; 2014 Mar; 9(1):89. PubMed ID: 24678590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.